AON-D21
Severe Community-Acquired Pneumonia (sCAP)
Phase 2Active
Key Facts
About Aptarion Biotech
Aptarion Biotech is a private, clinical-stage biotech company pioneering the development of L-aptamers, a novel class of synthetic therapeutics. The company's platform technology aims to combine the high specificity of biologics with the stability and manufacturing advantages of small molecules. Its lead program, AON-D21, is currently in a multinational Phase 2 trial for severe pneumonia, representing a potential first-in-class treatment for a high-unmet-need indication. Aptarion operates as a pre-revenue entity focused on advancing its proprietary platform through clinical validation.
View full company profile